| |
| |
|
| Insider
Information: |
Patel Sanj K |
| Relationship: |
|
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
63,012 |
|
|
Indirect Shares
|
109,795 |
|
|
| Direct
Value |
$1,214,241 |
|
|
|
Indirect Value
|
$2,115,750 |
|
|
| Total
Shares |
172,807 |
|
|
| Total
Value |
$3,329,991 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Synageva BioPharma Corp |
GEVA |
President & CEO, Direc... |
2015-06-22 |
0 |
2015-06-22 |
0 |
Premium* |
|
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
|
2024-04-08 |
63,012 |
2024-04-08 |
109,795 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-06-11 |
4 |
AS |
$40.89 |
$1,212,307 |
D/D |
(29,648) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-06-12 |
4 |
AS |
$40.48 |
$1,633,449 |
D/D |
(40,352) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-06-12 |
4 |
OE |
$0.95 |
$49,383 |
D/D |
40,352 |
41,383 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-25 |
4 |
AS |
$48.73 |
$716,867 |
D/D |
(14,711) |
18,235 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-25 |
4 |
OE |
$0.95 |
$45,319 |
D/D |
31,915 |
32,946 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-26 |
4 |
OE |
$1.70 |
$152,984 |
D/D |
52,190 |
70,425 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-26 |
4 |
AS |
$47.91 |
$3,331,548 |
D/D |
(69,394) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-29 |
4 |
AS |
$47.39 |
$753,264 |
D/D |
(15,895) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2013-07-29 |
4 |
OE |
$3.52 |
$55,950 |
D/D |
15,895 |
16,926 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-01-28 |
4 |
OE |
$0.95 |
$127,874 |
D/D |
51,329 |
52,360 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-01-28 |
4 |
AS |
$87.16 |
$4,531,045 |
D/D |
(51,329) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-01-29 |
4 |
OE |
$3.52 |
$179,418 |
D/D |
50,971 |
52,002 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-01-29 |
4 |
AS |
$87.19 |
$4,483,953 |
D/D |
(50,971) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-12-17 |
4 |
AS |
$87.25 |
$4,442,363 |
D/D |
(50,000) |
1,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2014-12-17 |
4 |
OE |
$1.70 |
$763,972 |
D/D |
50,000 |
51,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2015-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
72,000 |
73,031 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2015-06-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(73,031) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
President & CEO |
• • – |
2015-06-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(286) |
0 |
0 |
- |
|
93 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
